1Neuschwander-Tetri BA,Brunt EM,Wehmeier KR,et al.Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-g ligand rosiglitazone[ J ].Hepatology,2003,38(4):1008-1017. 被引量：1
3Promrat K,Lutchman G,Uwaifo GI,et al.A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis[J].Hepatology,2004,39 (1):188-196. 被引量：1
4Kiyici M,Gulten M,Gurel S,et al.Ursodeoxycholic acid and atorvastatin in the treatment of nonalcoholic steatohepatitis[J].Can J Gastroenterol,2003,17(12):713-718. 被引量：1
5Koruk M,Taysi S,Savas MC,et al.Oxidative stress and enzymatic antioxidant status in patients with nonalcoholic steatohepatitis[J].Ann Clin Lab Sci,2004,34(1):57-62. 被引量：1
6Merat S,Malekzadeh R,Sohrabi MR,et al.Probucol in the reatment of nonalcoholic steatohepatitis:an open-labeled study[J].J Clin Gastroenterol,2003,36(3):266-268. 被引量：1
7Harrison SA,Torgerson S,Hayashi P,et al.Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis[J].Am J Gastroenterol,2003,98(11):2485-2490. 被引量：1
8Diehl AM.Tumor necrosis factor and its potential role in insulin resistance and nonalcoholic fatty liver disease[J].Clin Liver Dis,2004,8(3):619-638. 被引量：1
9Satapathy SK,Garg S,Chauhan R,et al.Beneficial effects of tumor necrosis factor-alpha inhibition by pentoxifylline on clinical,biochemical,and metabolic parameters of patients with nonalcoholic steatohepatitis[J].Am J Gastroenterol,2004,99(10):1946-1952. 被引量：1
10Adams LA,Zein CO,Angulo P,et al.A pilot trial of pentoxifylline in nonalcoholic steatohepatitis[ J ].Am J Gastroenterol,2004,99 (12):2365-2368. 被引量：1
